Brief: Mirum Pharmaceuticals Announces Interim Data For Volixibat From VANTAGE PBC And VISTAS PSC Studies
17/06/2024 13:22
June 17 (Reuters) - Mirum Pharmaceuticals Inc MIRM.O :
* MIRUM PHARMACEUTICALS INC: VOLIXIBAT ACHIEVES POSITIVE
INTERIM
ANALYSES IN VANTAGE PBC AND VISTAS PSC STUDIES
* MIRUM: NO NEW SAFETY SIGNALS OBSERVED, ADVERSE EVENTS
SIMILAR
BETWEEN 20 MG AND 80 MG TREATMENT GROUPS
* MIRUM: FOUR PATIENTS EXPERIENCED SERIOUS ADVERSE EVENTS,
INCLUDING ONE IN PLACEBO ARM
Source text for Eikon: ID:nBwc9j3gTa
Further company coverage: MIRM.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Mirum Pharmaceuticals
See all newsMirum Pharmaceuticals Q3 net product sales surge, outlook raised
Brief: Mirum Pharmaceuticals Announces Positive Results From Cohort 2 Of The Pivotal Progress Study Of Atebrioz™ (Zilurgisertib) In Pediatric Patients Aged 6 To <12 Years With Fibrodysplasia Ossificans Progressiva
Mirum climbs on positive late-stage trial results for liver disease drug
US STOCKS ON THE MOVE-Mirum Pharmaceuticals, Meta, Boeing
U.S. STOCKS ON THE MOVE-Royal Caribbean Cruises, SpaceX